S&P 500   2,908.69 (-2.35%)
DOW   25,020.35 (-2.90%)
QQQ   202.42 (-1.57%)
AAPL   268.00 (-2.02%)
NVDA   259.27 (+2.64%)
MU   51.14 (+1.11%)
TSLA   636.09 (-6.32%)
T   35.08 (-1.82%)
F   6.82 (-2.15%)
NFLX   360.60 (-2.99%)
BAC   28.30 (-2.85%)
GILD   67.96 (-6.47%)
S&P 500   2,908.69 (-2.35%)
DOW   25,020.35 (-2.90%)
QQQ   202.42 (-1.57%)
AAPL   268.00 (-2.02%)
NVDA   259.27 (+2.64%)
MU   51.14 (+1.11%)
TSLA   636.09 (-6.32%)
T   35.08 (-1.82%)
F   6.82 (-2.15%)
NFLX   360.60 (-2.99%)
BAC   28.30 (-2.85%)
GILD   67.96 (-6.47%)
S&P 500   2,908.69 (-2.35%)
DOW   25,020.35 (-2.90%)
QQQ   202.42 (-1.57%)
AAPL   268.00 (-2.02%)
NVDA   259.27 (+2.64%)
MU   51.14 (+1.11%)
TSLA   636.09 (-6.32%)
T   35.08 (-1.82%)
F   6.82 (-2.15%)
NFLX   360.60 (-2.99%)
BAC   28.30 (-2.85%)
GILD   67.96 (-6.47%)
S&P 500   2,908.69 (-2.35%)
DOW   25,020.35 (-2.90%)
QQQ   202.42 (-1.57%)
AAPL   268.00 (-2.02%)
NVDA   259.27 (+2.64%)
MU   51.14 (+1.11%)
TSLA   636.09 (-6.32%)
T   35.08 (-1.82%)
F   6.82 (-2.15%)
NFLX   360.60 (-2.99%)
BAC   28.30 (-2.85%)
GILD   67.96 (-6.47%)
Log in

NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

$2.71
+0.01 (+0.37 %)
(As of 02/28/2020 01:38 PM ET)
Today's Range
$2.57
Now: $2.71
$2.71
50-Day Range
$2.23
MA: $2.98
$3.51
52-Week Range
$1.43
Now: $2.71
$5.69
Volume53,770 shs
Average Volume365,519 shs
Market Capitalization$146.91 million
P/E RatioN/A
Dividend YieldN/A
Beta0.67
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.71 million
Cash Flow$0.86 per share
Book Value$2.42 per share

Profitability

Net Income$31.85 million
Net Margins-227.76%

Miscellaneous

Employees106
Market Cap$146.91 million
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.


Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its earnings results on Tuesday, February, 25th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.01. The biotechnology company earned $5.61 million during the quarter, compared to analysts' expectations of $4.98 million. Strongbridge Biopharma had a negative net margin of 227.76% and a negative return on equity of 55.37%. View Strongbridge Biopharma's Earnings History.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for Strongbridge Biopharma.

What price target have analysts set for SBBP?

4 brokers have issued 12-month price targets for Strongbridge Biopharma's stock. Their forecasts range from $6.00 to $18.00. On average, they anticipate Strongbridge Biopharma's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 293.6% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

What is the consensus analysts' recommendation for Strongbridge Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

Headlines about SBBP stock have trended very negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Strongbridge Biopharma.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a drop in short interest in the month of February. As of February 14th, there was short interest totalling 362,300 shares, a drop of 8.0% from the January 30th total of 393,800 shares. Based on an average daily trading volume, of 449,100 shares, the short-interest ratio is currently 0.8 days. Approximately 1.1% of the company's stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 52)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 54)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.25%), Point72 Asset Management L.P. (1.20%), Renaissance Technologies LLC (1.18%), Geode Capital Management LLC (0.73%), Diversified Trust Co (0.37%) and Alambic Investment Management L.P. (0.22%). View Institutional Ownership Trends for Strongbridge Biopharma.

Which major investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Private Advisors LLC and Tredje AP fonden. View Insider Buying and Selling for Strongbridge Biopharma.

Which major investors are buying Strongbridge Biopharma stock?

SBBP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Diversified Trust Co, Point72 Asset Management L.P., Alambic Investment Management L.P., Bank of Montreal Can, Geode Capital Management LLC, State Street Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.71.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $146.91 million and generates $21.71 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or ($1.10) on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]


MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  340 (Vote Underperform)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel